Nyxoah (NASDAQ:NYXH) Trading Down 2.1%

Nyxoah S.A. (NASDAQ:NYXH)’s share price was down 2.1% during trading on Friday . The company traded as low as $8.43 and last traded at $8.43. Approximately 10,643 shares were traded during trading, a decline of 72% from the average daily volume of 38,530 shares. The stock had previously closed at $8.61.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Oppenheimer reduced their target price on Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Stifel Nicolaus lowered their target price on Nyxoah from $27.00 to $19.00 and set a “buy” rating for the company in a research note on Monday, June 24th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Nyxoah in a research note on Wednesday, August 7th. Finally, Cantor Fitzgerald lowered their price objective on shares of Nyxoah from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Wednesday, August 7th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $17.20.

Nyxoah Trading Down 2.1 %

The company has a debt-to-equity ratio of 0.09, a current ratio of 5.47 and a quick ratio of 5.16. The business’s 50-day moving average is $8.25 and its two-hundred day moving average is $9.73. The firm has a market cap of $210.24 million, a P/E ratio of -5.14 and a beta of 1.43.

Nyxoah (NASDAQ:NYXH) last released its earnings results on Tuesday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.01). Nyxoah had a negative net margin of 908.32% and a negative return on equity of 42.00%. The company had revenue of $0.83 million during the quarter, compared to analyst estimates of $1.93 million. As a group, analysts predict that Nyxoah S.A. will post -1.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Iron Triangle Partners LP bought a new stake in shares of Nyxoah in the 1st quarter valued at about $3,413,000. CVI Holdings LLC bought a new stake in Nyxoah in the second quarter valued at approximately $1,292,000. Finally, Ikarian Capital LLC acquired a new stake in shares of Nyxoah in the first quarter valued at approximately $684,000.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.